Compare Stocks: ANIX, KMDA, PBYI, and QTTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.48 -3.3%	$3.31	$2.32 ▼ $5.46	$122.48M	0.55	223,446 shs	214,710 shs
KMDA Kamada	$8.29 +0.4%	$7.39	$6.50 ▼ $9.35	$474.99M	0.86	164,224 shs	55,081 shs
PBYI Puma Biotechnology	$9.06 -1.9%	$8.37	$4.30 ▼ $9.51	$476.97M	1.22	326,210 shs	235,035 shs
QTTB Q32 Bio	$15.03 -6.9%	$14.90	$1.62 ▼ $23.57	$480.78M	0.23	423,652 shs	353,342 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-3.33%	-6.20%	0.00%	+28.89%	+17.97%
KMDA Kamada	+0.36%	+0.61%	+18.26%	+6.15%	+16.27%
PBYI Puma Biotechnology	-1.95%	-1.95%	+16.01%	+26.36%	+77.65%
QTTB Q32 Bio	-6.93%	-5.89%	+2.66%	+36.02%	+773.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.48 -3.3%	$3.31	$2.32 ▼ $5.46	$122.48M	0.55	223,446 shs	214,710 shs
KMDA Kamada	$8.29 +0.4%	$7.39	$6.50 ▼ $9.35	$474.99M	0.86	164,224 shs	55,081 shs
PBYI Puma Biotechnology	$9.06 -1.9%	$8.37	$4.30 ▼ $9.51	$476.97M	1.22	326,210 shs	235,035 shs
QTTB Q32 Bio	$15.03 -6.9%	$14.90	$1.62 ▼ $23.57	$480.78M	0.23	423,652 shs	353,342 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-3.33%	-6.20%	0.00%	+28.89%	+17.97%
KMDA Kamada	+0.36%	+0.61%	+18.26%	+6.15%	+16.27%
PBYI Puma Biotechnology	-1.95%	-1.95%	+16.01%	+26.36%	+77.65%
QTTB Q32 Bio	-6.93%	-5.89%	+2.66%	+36.02%	+773.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$8.50	144.25% Upside
KMDA Kamada	3.00	Buy	$13.00	56.82% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-33.77% Downside
QTTB Q32 Bio	2.71	Moderate Buy	$31.00	106.25% Upside

Current Analyst Ratings Breakdown

Latest ANIX, KMDA, PBYI, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/21/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
7/28/2026	QTTB Q32 Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $36.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	563.76	N/A	N/A	$0.42 per share	8.29
KMDA Kamada	$180.46M	2.64	$0.61 per share	13.53	$4.69 per share	1.77
PBYI Puma Biotechnology	$228.40M	2.05	$0.82 per share	11.08	$2.68 per share	3.38
QTTB Q32 Bio	$53.74M	8.33	$1.41 per share	10.65	$3.56 per share	4.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.31	N/A	N/A	N/A	N/A	-71.12%	-62.88%	9/9/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	21.82	13.82	0.67	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	17.42	50.33	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	5.01	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)

Latest ANIX, KMDA, PBYI, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A
6/10/2026	Q2 2026	ANIX Anixa Biosciences	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.57%	N/A	34.21%	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Latest ANIX, KMDA, PBYI, and QTTB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	9.79	9.79
KMDA Kamada	N/A	4.06	2.29
PBYI Puma Biotechnology	N/A	2.91	2.64
QTTB Q32 Bio	N/A	20.30	20.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
KMDA Kamada	20.38%
PBYI Puma Biotechnology	61.29%
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
KMDA Kamada	36.10%
PBYI Puma Biotechnology	22.20%
QTTB Q32 Bio	34.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable
QTTB Q32 Bio	39	29.77 million	19.51 million	N/A

ANIX, KMDA, PBYI, and QTTB Headlines

Recent News About These Companies

Q32 Bio (NASDAQ:QTTB) Insider Sells 2,798 Shares of Stock

August 28 at 7:07 AM | insidertrades.com

Q32 Bio (NASDAQ:QTTB) Insider Sells $46,334.88 in Stock

August 27 at 5:21 PM | marketbeat.com

Lee Kalowski Sells 3,972 Shares of Q32 Bio (NASDAQ:QTTB) Stock

August 27 at 5:21 PM | marketbeat.com

Insider Selling: Q32 Bio (NASDAQ:QTTB) CEO Sells 9,845 Shares of Stock

August 27 at 5:07 PM | marketbeat.com

Q32 Bio: The Efficacy Is Modest, The Valuation Is Not

August 24, 2026 | seekingalpha.com

Traders Buy Large Volume of Call Options on Q32 Bio (NASDAQ:QTTB)

August 23, 2026 | americanbankingnews.com

Q32 Bio Sees Unusually Large Options Volume (NASDAQ:QTTB)

August 21, 2026 | marketbeat.com

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

August 17, 2026 | zacks.com

Q32 Bio (NASDAQ:QTTB) stock in focus after mid-stage trial data

August 16, 2026 | kalkinemedia.comK

Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB

August 14, 2026 | marketbeat.com

HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB)

August 7, 2026 | marketbeat.com

Q32 Bio tops estimates as alopecia drug advances toward late-stage trials

August 6, 2026 | seekingalpha.com

Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 6, 2026 | marketbeat.com

Q32 Bio (NASDAQ:QTTB) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

August 5, 2026 | marketbeat.com

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026 | prnewswire.com

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

July 31, 2026 | zacks.com

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

July 20, 2026 | zacks.com

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

July 17, 2026 | seekingalpha.com

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

July 15, 2026 | zacks.com

Q32 Bio prices $200M equity raise

July 15, 2026 | msn.com

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

July 14, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, KMDA, PBYI, and QTTB Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.48 -0.12 (-3.33%)

As of 08/28/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Kamada NASDAQ:KMDA

$8.29 +0.03 (+0.36%)

As of 08/28/2026 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Puma Biotechnology NASDAQ:PBYI

$9.06 -0.18 (-1.95%)

As of 08/28/2026 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Q32 Bio NASDAQ:QTTB

$15.03 -1.12 (-6.93%)

As of 08/28/2026 04:00 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, KMDA, PBYI, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, KMDA, PBYI, and QTTB Earnings

Compare Dividends

Latest ANIX, KMDA, PBYI, and QTTB Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, KMDA, PBYI, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, KMDA, PBYI, and QTTB Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

Q32 Bio NASDAQ:QTTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools